Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AdCOVID in Healthy Adults
NCT04679909Phase 1Completed
- Sponsor
- Altimmune, Inc.
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Adenoviral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AdCOVID in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Altimmune, Inc. Primary endpoints: Reactogenicity at 7 days and Adverse Events. Started Feb 2021; status: completed.
02
Drugs
AdCOVID
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04679909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679909.